The pharmaceutical patent cliff narrative has dominated investor and analyst conversations for two decades, but it increasingly misses the point
Drug Delivery Complexity: The IP Moat That Keeps Generics Out for Decades Read Post »
What Nonprofit Pharma Actually Is (And Isn’t) Understanding the Structural Distinction ‘Nonprofit pharma’ covers at least three distinct entity types,
1. The Economics Driving the Biosimilar IP War The global biosimilar market is not a niche regulatory experiment. It is
The Biosimilar Patent Dance and PTAB Playbook: How to Win the Biologic IP War Read Post »
The definitive guide to sildenafil IP strategy, authorized generics, evergreening tactics, and what the Viagra case teaches pharma teams about
The U.S. spent roughly $400 billion on specialty drugs in 2022. A record $9.4 billion of that was clawed back
The Unified Patent Court went live on June 1, 2023. Pharma IP teams and biotech portfolio managers who treated that
The Economics Behind Low-Competition Generic Markets Why Price Decay Makes Niche Sourcing Mandatory Generic drug markets operate on a compression
1. Who This Guide Is For This guide is written for IP counsel, portfolio managers, R&D leads, and institutional investors
AI Drug Patents: The Complete IP Strategy Guide for Pharma and Biotech Read Post »
Executive Summary The global biopharmaceutical sector has entered a decisive inflection point in early 2026, characterized by the convergence of
Sign in or create a free account to read this DrugPatentWatch article
